Nanomedicine: Nanotechnology, Biology and Medicine
Volume 5, Issue 1 , Pages 42-45, March 2009

An iodinated liposomal computed tomographic contrast agent prepared from a diiodophosphatidylcholine lipid

Department of Internal Medicine, Division of Cardiology, The University of Texas Health Science Center at Houston, Houston, Texas, USA

Received 17 March 2008; accepted 25 June 2008. published online 10 September 2008.

Abstract 

Herein we report a novel vesicle-forming iodinated contrast agent for applications in computed tomographic (CT) imaging and drug delivery. Specifically, we have chemically modified a phosphatidylcholine lipid that is commonly used in liposome formation to create an iodinated lipid that self-assembles into ~50-150 nm iodoliposomes possessing as-prepared imaging contrast functionality. These iodoliposomes are structurally organized such that the iodinated moieties are contained within the vesicle's bilayer, leaving the liposomal interior unoccupied and thus available for encapsulating drugs. The iodoliposomes were characterized using electron microscopy and dynamic light scattering. We also calculated the iodoliposomes' iodine encapsulation efficiency, which was sufficient for use in current CT imaging protocols. These iodinated liposomes could also serve as multifunctional carriers upon the encapsulation of pharmaceutical agents, permitting simultaneous CT imaging and therapeutic treatment. Alternatively, the commercially available iodinated contrast agent iohexol could be encapsulated inside the iodoliposomes' aqueous core to further enchance their imaging contrast.

Key words: Iodinated liposome, Nanoparticle contrast agent, Functional nanoparticles

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 10.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Research support came from the National Aeronautics and Space Administration (NNJ05HE75A) and the Department of Defense/Telemedicine and Advanced Technology Research Center (W81XWH-04-20035T5 and DAMD17-01-2-0047). Nuclear magnetic resonance facility support was provided by the National Cancer Institute Cancer Center Support Grant CA016672.

PII: S1549-9634(08)00092-0

doi:10.1016/j.nano.2008.06.007

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 5, Issue 1 , Pages 42-45, March 2009